Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 11, 2009

Knome to Offer Genome Sequencing through SeqWright

  • Knome will offer its personal genome sequencing and analysis services through SeqWright’s CLIA-certified laboratory. In the collaboration, SeqWright will process and sequence client samples using SOLiD and 454 platforms, while Knome will continue to perform all data analysis and interpretation services.

    Knome currently provides two separate sequencing and analysis services for consumers: KnomeSELECT™ and KnomeCOMPLETE™. Launched last month, KnomeSELECT enables consumers to obtain the sequence of their genes as well as a customized analysis of the results. KnomeCOMPLETE is the company’s flagship complete genome sequencing service.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »